Articles tagged with Positron Emission Tomography
Research published in the International Journal of Biomedical Engineering and Technology reveals a wavelet transform approach that improves medical imaging. The technique boosts the signal-to-noise ratio and reduces artifacts, allowing for earlier disease detection and diagnosis.
Researchers emphasize the need to improve brain imaging accuracy for dementia diagnosis and progression prediction. MRI scans and PET scans show promise, but current methods are not sensitive or accurate enough for widespread adoption.
Researchers developed a molecular imaging biomarker that detects fast-growing primary prostate cancer and distinguishes it from benign prostate lesions. The new PSMA-based PET imaging technique was more specific than MR imaging for detecting clinically significant high-grade prostate cancer lesions.
Researchers have developed a new probe that can detect blood clots in any part of the body using positron emission tomography (PET). The probe, called FBP8, contains copper-64 and has shown promise in detecting blood clots in rats, paving the way for future human trials.
A new approach to visualize glucose uptake activity in single living cells has been developed by Columbia University researchers. This technique uses stimulated Raman scattering imaging with a small alkyne tag to generate a strong Raman signal, allowing for high-sensitivity imaging of glucose uptake at the cellular level.
Dr. Hartmuth Kolb was recognized for his pioneering research on neurofibrillary tangles (NFTs) and Alzheimer's disease (AD). His PET imaging tracers showed promise in evaluating NFT pathology, holding potential for disease diagnosis and monitoring.
A study found that 86% of women with early-stage breast cancer in Ontario underwent imaging to detect metastatic cancer, despite international guidelines recommending against it. The use of advanced imaging increased and varied by geographic region and hospital type, highlighting a need for improved knowledge translation strategies.
A new technique combines dynamic PET imaging with parametric tumor mapping to detect tumors and metastases throughout the body, providing quantitative evaluation and improved contrast. This method has the potential to be used for early diagnosis and more accurate prognosis of various cancers.
A novel PET technique tracks microglial activation in response to endotoxin, shedding light on neuroinflammatory diseases like Alzheimer's and depression. The study's findings could lead to new drug treatments by targeting immune dysfunction.
A new molecular imaging agent has been developed to detect prostate cancer that has spread to other tissues. The agent targets the PSMA enzyme, which is associated with prostate cancer, and has shown high accuracy in detecting disease sites, including those not identified by conventional methods.
A specialized PET tracer has been developed to visualize the function of nerve cells that lead to neuronal loss and cognitive decline in neurodegenerative diseases. The tracer binds to a transporter of the neurotransmitter acetylcholine, allowing for the quantification of cholinergic neuron loss and its effects on cognition.
Research shows amyloid PET scans improve diagnosis and treatment outcomes for Alzheimer's patients, especially when used after an indeterminate FDG-PET scan. The study found that 17% of patients who received an amyloid scan experienced statistically significant improvements in cognition over a two-year follow-up.
A new study found that PET/CT scans are highly sensitive for detecting relapsed non-Hodgkin lymphoma, with a sensitivity rate of 95.1%. This breakthrough has significant implications for patient care, as early diagnosis can lead to improved treatment outcomes and longer survival rates.
Researchers have developed a cloud-based software that analyzes and standardizes PET imaging data, allowing for earlier and more accurate diagnoses of Alzheimer's disease. The program uses machine learning to compare patients' scans with normal and abnormal scans, providing consistent results and quantifying PET data accurately.
A new theranostic agent, I-124 PEG-AVP0458, has shown promise in targeting both ovarian and prostate cancer cells for imaging and treatment. The drug compound attaches itself to the targeted tumor sites via positron emission tomography (PET) scanners, enabling personalized cancer therapy.
Scientists have developed a novel PET tracer that can pinpoint thrombi throughout the body with over 97% accuracy. The tracer, Cu-64 FBP8, targets fibrin in blood clots and reflects thrombus age, enabling clinicians to choose more effective treatments.
Townsend's contributions to nuclear medicine have been transformative, introducing 3D PET imaging and the combined PET/CT scanner. His work has improved the signal-to-noise of reconstructed images without increasing detector material cost.
Phelps was recognized for his contributions to nuclear medicine and molecular imaging, including the invention of PET scanners. His work has improved outcomes for patients with cancer, neurological disorders, and cardiovascular disease.
Researchers developed new PET probes composed of labeled antibody fragments that can detect pancreatic cancer tumors too small to be detected with conventional methods. These probes show promise for targeted imaging and tracking the delivery of drugs.
Researchers developed new PET probes using labeled antibody fragments to visualize tumors in mice. These probes could provide more information about tumors and help doctors choose treatment options.
Two studies analyze amyloid prevalence among adults of varying ages and its association with cognitive impairment. The findings indicate that key risk factors for Alzheimer's disease are also risk factors for amyloid positivity in cognitively normal persons.
A novel approach harnessing positron emission tomography (PET) imaging identifies areas of immune cell activity associated with inflammation or tumor development. This method offers a potential breakthrough in diagnostics and monitoring efficacy of cancer therapies.
A new imaging tool found a strikingly similar pattern of abnormal protein deposits in the brains of retired NFL players with concussions, which may help identify brain disorders like CTE. The study also shows differences in brain imaging patterns between concussed athletes and healthy individuals.
The study found that cardiac PET/CT imaging diagnosed heart problems with certainty 88% of the time, while SPECT imaging gave a clear diagnosis only 30% of the time. This technology reduces unnecessary invasive procedures and radiation exposure by a factor of 10.
A study of over 1,200 cognitively normal individuals aged 30-95 found that men experienced worse memory decline and lower hippocampal volume than women, while APOE ?4 carriers had greater amyloid accumulation from age 70 onwards.
Researchers found PET/MR to be superior in diagnosing foot pain causes, providing more diagnostic information and higher certainty than PET/CT. This non-invasive method offers an important tool for sensitive diagnosis of foot pathologies.
Advanced medical imaging increases diagnostic confidence and facilitates rapid diagnoses, leading to better clinical decisions. Primary care physicians perceive imaging as crucial for quality patient care, particularly for sicker patients.
Research finds accumulated brain damage linked to memory deficits and mood regulation in former NFL players, supporting calls for improved athlete protection from concussion. PET scans show concentrated zones of high translocator protein levels, indicating brain injury and potential long-term neurological risk.
University at Buffalo researchers have designed a nanoparticle that can be detected by six medical imaging techniques, including CT scanning, PET scanning, and photoacoustic imaging. This technology has the potential to provide doctors with clearer pictures of patients' organs and tissues, enabling faster diagnosis and treatment.
Researchers used positron emission tomography (PET) and computed tomography (CT) imaging to monitor antibiotic treatment effects in TB-infected monkeys and humans. Changes in PET/CT scans over time accurately predicted treatment outcomes, potentially shortening clinical trials and saving resources.
Researchers found changes in metabolic activity of key brain region after successful treatment with psychodynamic therapy. Patients who completed therapy had a greater than 50 percent reduction in depression symptoms.
Research suggests that pathological gamblers have a different response to the brain's opioid system, resulting in reduced feelings of euphoria compared to healthy individuals. This altered response may contribute to the addictive nature of gambling.
A new technique using bioimpedance measurement reduces image degradation caused by respiratory motion during PET scans, enabling more accurate detection of cancers and heart conditions. This improved imaging quality can lead to better diagnosis reliability and treatment response monitoring.
A new MRI technique called arterial spin labeling (ASL) can detect signs of cognitive decline in the brain even before symptoms appear. The technique measures brain perfusion and has the potential to serve as a biomarker for very early diagnosis of preclinical dementia.
A new experimental PET tracer effectively diagnoses chronic traumatic encephalopathy (CTE) while patients are still alive. The technology differentiates CTE from other forms of dementia, enabling estimates of prevalence and risk. This breakthrough improves diagnosis and treatment for athletes and others exposed to repeated head trauma.
Recent EORTC Imaging Group review highlights MRI and PET's potential for early detection of bone metastases and monitoring treatment response. The study emphasizes the need to overcome current limitations, such as those related to imaging techniques' sensitivity and specificity.
A PET study found that acupuncture at Yongquan acupoints induced stronger neuronal activity than sham acupoints, suggesting a potential mechanism for improving patients with DOC. The putamen, cingulate cortex, frontal lobe, and cerebellum were involved in conscious thought.
Researchers used PET imaging to study Tongxinluo's neuroprotective effects in rats. The study found that Tongxinluo reduced brain damage after middle cerebral artery occlusion, highlighting its potential as a treatment for acute stroke.
A new imaging agent has been developed for functional imaging of the intestine, potentially leading to better diagnosis and treatment of gut diseases. The agent uses a combination of photoacoustic imaging and positron emission tomography to provide high-definition images of the intestine in relation to the entire body.
Research trials report associations between decreased odor identification and loss of brain cell function, as well as beta-amyloid buildup in the eye with progression to Alzheimer's. Early detection is crucial for intervention and prevention, with promising results suggesting potential methods for early detection in a research setting.
Researchers developed a non-invasive imaging technique to track beta cell status in type 1 diabetes patients. The PET scan detects the amount of radiotracer in the pancreas, indicating the overall amount or volume of active beta cells present.
Researchers used SPECT and PET systems to detect inflammation involved in osteoarthritis, giving doctors a clear read on chronic pain and possible joint destruction. Radiolabeled anti-FAP antibodies showed significantly increased imaging agent uptake in inflamed joints.
Researchers can conduct five different imaging studies in one scan with the Opti-SPECT/PET/CT system, providing comprehensive data on anatomy and physiological processes. The device allows for minimally invasive studies with a single dose of anesthesia, enabling scientists to develop new drug discovery methods.
A new study reveals that PET/MR imaging is highly effective in detecting coronary artery disease, outperforming traditional SPECT methods. The hybrid technique provides a comprehensive view of the heart, combining anatomical and functional information for more accurate diagnoses.
A new PSMA-based imaging agent, F-18 DCFBC PET/CT, has been developed to detect prostate cancer and monitor treatment response. The study shows the agent's effectiveness in detecting both castration-sensitive and castration-resistant forms of the disease.
A new antibody-based molecular imaging agent has been developed to target the HER3 receptor in breast cancer, which may lead to better diagnosis and treatment of high-risk cases. This approach could also help identify patients who would benefit from additional therapies.
A novel F-18 labeled tracer, F-18 THK5117, selectively binds to tau/neurofibrillary tangles in Alzheimer's brains. This study demonstrates the potential for F-18 THK5117 to develop new anti-dementia drugs.
Siegel's work on PET has led to a major advance in nuclear medicine science, with a focus on evidence-based clinical trials and widespread acceptance of imaging studies. He is recognized for his visionary leadership in developing scientific methodology.
Researchers at Princeton University have developed a faster method to create 18F radiotracers, which are used to detect and track certain diseases in patients. The new method avoids harsh conditions that scramble the placement of chemical bonds, resulting in improved efficiency and accuracy.
The new diffuse optical tomography (DOT) technology tracks brain processes in multiple regions and networks, providing a non-radiation alternative to fMRI. DOT has the potential to be helpful in many medical scenarios as a surrogate for functional MRI.
Acupuncture at Yongquan acupoints induced stronger neuronal activation than sham points, increasing synaptic activity in areas involved in conscious thought. This may explain the improvement of patients with disorder of consciousness.
Researchers used breath analysis to detect lung cancer with a sensitivity comparable to PET scanning and a higher specificity, distinguishing patients with benign disease from those with early-stage cancer. The method shows promise as a non-invasive diagnostic tool, expediting treatment for patients with lung cancer.
Researchers have made a groundbreaking discovery using MRI scans to identify brown adipose tissue in adults, a major step towards developing new weight loss treatments. The study's findings could lead to the creation of safe and effective therapies that activate brown fat to promote energy expenditure.
A new study published in The Lancet found that functional brain imaging techniques, such as PET and fMRI, can reliably predict which vegetative patients have the potential to recover consciousness. The research suggests that these techniques can complement standard behavioral assessments to identify patients with a higher chance of lon...
Researchers used functional PET imaging to show that neuroinflammation is higher in CFS/ME patients compared to healthy people. The study found associations between inflammation in certain brain areas and symptoms such as impaired cognition.
Scientists used PET imaging to visualize copper distribution in the body of mice with Menkes disease, laying groundwork for human studies. The study found that combining copper injections with disulfiram enhances copper accumulation in the brain without kidney damage.
A study found that preoperative PET imaging reduced unnecessary surgeries for non-small cell lung cancer patients by 50%, eliminating approximately half of them. The use of PET increased during the study period, suggesting its potential to change policy and recommendations regarding tumor staging.
Researchers detected early evidence of Alzheimer's disease using brain scans and found that those with positive scans had a faster rate of decline on memory, language, and reasoning over three years. This biomarker could help clinicians better evaluate and treat patients at risk for cognitive decline.
A study published in Cancer Epidemiology, Biomarkers & Prevention found that cancer patients seeking information from non-clinician sources were more likely to receive PET scans. The study suggests that exposure to cancer-related information and promotional materials may drive the use of unnecessary imaging procedures.
Researchers developed a novel sugar-based tracer contrast agent to aid in the detection of inflamed and vulnerable artery plaques. The new tracer, fluorodeoxymannose (FDM), shows promise in targeting high-risk plaques more specifically than traditional glucose-based tracers.